ALLO Latest Press Releases

-- November 9, 2026 --

Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease Globe Newswire 8:00 AM

-- November 5, 2026 --

Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update Globe Newswire 4:02 PM

-- November 3, 2026 --

Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting Globe Newswire 8:00 AM

-- October 29, 2026 --

Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data Globe Newswire 8:30 AM

-- October 26, 2026 --

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences Globe Newswire 8:30 AM

-- September 2, 2026 --

Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker Globe Newswire 8:30 AM

-- August 31, 2026 --

Allogene Therapeutics Announces Participation in September Investor Conference Globe Newswire 8:30 AM

-- August 12, 2026 --

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update Globe Newswire 4:05 PM

-- August 4, 2026 --

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update Globe Newswire 8:30 AM

-- July 29, 2026 --

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma Globe Newswire 8:30 AM

-- July 15, 2026 --

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes